🔗 Share this article

As the United States proceeds with historic changes to its vaccine schedules, one figure has emerged in a surprising turn: Høeg, a Danish American physician and public health researcher who initially gained attention by casting doubt on coronavirus vaccinations during the pandemic and has focused upon potential fatalities following Covid immunization in her short position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Public health authorities had intended to announce major revisions to the childhood vaccine schedule recently, synchronizing the US with the Danish vaccine program, it is understood – a significant shift that would put the US out of alignment with much of the world with insufficient data for benefit. The announcement has been delayed until the coming year.

Rather than the top vaccines chief, Dr. Høeg is set to address the audience at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to lead the office this year.

A New Direction at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad solidify control at the agency – and it signals a greater focus upon dismantling previously authorized vaccines at the FDA.

The new acting director has frequently advocated for discontinuing certain childhood shot schedules in the US to become more similar to Denmark's approach, a society with universal health coverage and a number of inhabitants about the size of the state of Wisconsin.

So far statements, she has continued to focus on vaccines – typically the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Qualifications

Dr. Høeg has no apparent background in drug development, approval processes or leadership, which has been customary for previous heads of the biologics center. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for leading the CDER, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a large organization. She has no expertise in industry regulation.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who ran CBER have had.”

CDER has an immense portfolio at the FDA, the former commissioner emphasized.

“The public just pays attention on the new drug program, but the generic drug division approves thousands of generic medications. There’s a biosimilars program, OTC medication office and more, and each of these need to be supervised,” Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a major management element to the role, which manages over 5,000 employees. “It’s a massive administrative position, if you perform it correctly,” the former official concluded.

Agency Reaction and Disputed Initiatives

When asked about inquiries about Dr. Høeg's credentials and whether this appointment represents more teamwork among agency officials on immunizations, a spokesperson responded that the “questions are based on inaccurate assumptions”.

“Her experience is consistent with the functions of her role,” the official explained, noting the time Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a controversial one-day drug-approval program that reportedly troubled her former heads. “How are these therapies being chosen for this voucher program? Who takes the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards laxer regulations of pharmaceuticals, with the exception of immunizations.”

Documented History on Immunizations

With vaccines, Dr. Høeg has a clearer, if troubling, past, Howard have noted. She released a research paper using unverified public submissions to determine the incidence of heart inflammation following Covid immunization. She advised the state of Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are riskier than they are.

Included in her “desired changes” for the new government featured changing regulations for new vaccines and ending “optional” vaccines, she remarked following the vote on a audio program. At the FDA, Høeg has reportedly suggested excluding teenage boys from obtaining Covid vaccinations.

“She’s an thorough dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the data in a extremely deceptive, untruthful way,” Howard said.

Taking Control and a “Revenge Tour”

Høeg aligned with other dissenters, {like|